879872-53-4

Upstream product

• 879872-48-7 (S)-4-{(2R,6R)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-4-methylene-tetrahydro-pyran-2-yl}-butane-1,3-diol 
• 879872-49-8 4-((2S,4S)-4-{(2R,6R)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-4-methylene-tetrahydro-pyran-2-ylmethyl}-[1,3]dioxan-2-yl)-2-(4-methoxy-benzyloxymethyl)-oxazole 

Downstream Products

• 879872-50-1 Methanesulfonic acid 4-((2S,4S)-4-{(2R,6R)-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-4-methylene-tetrahydro-pyran-2-ylmethyl}-[1,3]dioxan-2-yl)-oxazol-2-ylmethyl ester 

Relevant academic research and scientific papers

Phorboxazole compounds and methods of their preparation

Novel macrolactone compounds, their methods of preparation, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the macrolactone compounds may be useful, inter alia, for treating various cancers, inducing apoptosis in malignant cells, or inhibiting cancer cell division.

Design and synthesis of a potent phorboxazole C(11-15) acetal analogue

We disclose here the design, synthesis, and biological evaluation of simplified Z- and E-C(2-3) alkynyl phorboxazole C(11-15) acetals (+)-7Z and (+)-7E, wherein the Z-isomer proved to be a potent nanomolar cytotoxic agent. Reevaluation of (+)-C(45-46) E-c